FY2024 EPS Estimates for Regeneron Pharmaceuticals, Inc. Boosted by Cantor Fitzgerald (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Analysts at Cantor Fitzgerald upped their FY2024 earnings estimates for shares of Regeneron Pharmaceuticals in a research note issued to investors on Monday, July 22nd. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will earn $35.16 per share for the year, up from their prior estimate of $34.90. Cantor Fitzgerald has a “Neutral” rating and a $1,000.00 price target on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.02 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%.

A number of other equities analysts have also weighed in on REGN. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Monday, June 17th. Truist Financial restated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,074.95.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $1,064.19 on Wednesday. The firm has a market cap of $117.26 billion, a PE ratio of 31.44, a PEG ratio of 2.19 and a beta of 0.13. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 1-year low of $723.56 and a 1-year high of $1,106.16. The company has a fifty day moving average price of $1,031.92 and a 200 day moving average price of $975.57.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,074 shares of company stock worth $64,546,123. Insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Nordea Investment Management AB raised its holdings in Regeneron Pharmaceuticals by 23.2% in the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after acquiring an additional 5,495 shares during the period. Sierra Summit Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $1,011,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $1,232,000. Sei Investments Co. increased its holdings in shares of Regeneron Pharmaceuticals by 8.1% during the first quarter. Sei Investments Co. now owns 24,407 shares of the biopharmaceutical company’s stock worth $23,487,000 after purchasing an additional 1,839 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $749,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.